Analyst Jason McCarthy from Maxim Group maintained a Buy rating on Immutep (IMMP – Research Report) and keeping the price target at $12.00.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Jason McCarthy has given his Buy rating due to a combination of factors surrounding Immutep’s recent clinical trial results. The company reported promising data from its Phase 1 INSIGHT-003 study, which evaluated a triple combination therapy involving eftilagimod, chemotherapy, and Keytruda in first-line metastatic non-small cell lung cancer (1L NSCLC). The study demonstrated an impressive overall response rate of 60.8% and a disease control rate of 90.2%, irrespective of PD-L1 expression levels.
The results are particularly noteworthy in patients with low or negative PD-L1 expression, a group that constitutes a significant portion of the 1L NSCLC population. In this subgroup, the combination therapy showed a 59.6% response rate, outperforming historical controls. These findings, coupled with the ongoing Phase 3 TACTI-004 study, suggest a strong potential for regulatory approval and market adoption, making Immutep’s stock an attractive investment opportunity.